S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
Your Money is Not Safe (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
Your Money is Not Safe (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
Your Money is Not Safe (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
Your Money is Not Safe (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Free Trial
CVE:DMA

DiaMedica Therapeutics (DMA) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free DMA Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
27,250 shs
Average Volume
6,619 shs
Market Capitalization
C$36.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

DMA Stock News Headlines

February 16, 2024 | morningstar.com
DiaMedica Therapeutics Inc DMAC
March 31, 2023 | seekingalpha.com
DiaMedica Therapeutics Inc. (DMAC) Q4 2022 Earnings Call Transcript
April 19, 2024 | InvestorPlace (Ad)
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
February 24, 2023 | nasdaq.com
Cerevel Therapeutics Holdings (CERE) Shares Cross Below 200 DMA
October 26, 2022 | seekingalpha.com
DiaMedica stock slides 17% after hours as FDA maintains clinical hold on DM199 trial
August 12, 2022 | finance.yahoo.com
MEXC Activated the "Investor Protection Fund" in Response to the Dragoma (DMA) Incident, and Launched the "Potion" Airdrop Compensation Benefits
July 8, 2022 | marketwatch.com
DiaMedica Therapeutics Announces Clinical Hold of DM199 Trial, Shares Fall 31%
May 7, 2022 | seekingalpha.com
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q1 2022 Results - Earnings Call Transcript
See More Headlines
Receive DMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
CVE
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
CVE:DMA
CUSIP
N/A
CIK
N/A
Web
www.diamedica.com
Phone
+1-763-4965454
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.48
Quick Ratio
3.37

Sales & Book Value

Annual Sales
C$503,657.00
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
9.33
Book Value
C$0.17 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
7,856,880
Free Float
N/A
Market Cap
C$36.38 million
Optionable
Not Optionable
Beta
N/A
Beginners Guide To Retirement Stocks Cover
Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Rick Pauls M.B.A. (Age 48)
    MBA, Pres, CEO & Director
  • Dr. Todd A. Verdoorn (Age 58)
    Chief Scientific Officer
  • Mr. Scott B. Kellen C.A. (Age 54)
    CFO & Company Sec.
  • Mr. Edward B. Rady (Age 70)
    Chief Commercial Advisor
  • Dr. Dennis D. Kim M.D. (Age 49)
    MBA, Consulting Chief Medical Officer

Key Competitors

View All Competitors

This page (CVE:DMA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research